Results 171 to 180 of about 6,360,215 (357)
Factorial and Construct Validity of the Italian Positive and Negative Affect Schedule (PANAS) [PDF]
Antonio Terracciano+2 more
openalex +1 more source
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani+14 more
wiley +1 more source
Daily Marital Interactions and Positive Affect During Marital Conflict Among Newlywed Couples [PDF]
Janice Driver, John M. Gottman
openalex +1 more source
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez+17 more
wiley +1 more source
Positive Emotional Priming of Facial Affect Perception in Females is Diminished by Chemosensory Anxiety Signals [PDF]
Bettina M. Pause
openalex +1 more source
Ubiquitination of transcription factors in cancer: unveiling therapeutic potential
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley +1 more source
Development of the Japanese version of Positive and Negative Affect Schedule (PANAS) scales
A. Sato, Asako Yasuda
openalex +2 more sources
Upstaging based solely on positive peritoneal washing does not affect outcome in endometrial cancer [PDF]
Oluwole Fadare+5 more
openalex +1 more source
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen+12 more
wiley +1 more source